Aug. 19 at 2:24 PM
$IMMX IMMX holders need to know the tremendous long term potential. Don’t trade it short term. In the short to intermediate term, IMMX is a strong buyout candidate at
$100 per share. In the intermediate term after commercial launch, gross margin is probably
$400,000 per person. Initially 3,000 RR patients in the U.S. that is
$1.2 billion gross profits. Assume
$200 million operating expense, the net profits is
$1 billion. That is
$14 earnings per share. Assume PE is 30, share price is
$420 per share. After EU is launched, it will be
$840 per share. After first line is approved and patients doubles, the share price will be
$1,680 per share.
